[Effectiveness and safety of generic version of lamivudine/tenofovir and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2012-2014].

Author: AmarilesPedro, CastañedaCarol, GalindoJaime, Mueses-MarínHéctor F

Paper Details 
Original Abstract of the Article :
BACKGROUND: Clinical studies aimed to evaluating the quality of generic drugs may be useful to strengthen policies of access to combined antiretroviral therapy (cART). AIM: To describe the effectiveness and safety of the generic schema lamivudine/tenofovir/efavirenz (3TC/TDF/EFV) in patients with H...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.4067/S0716-10182019000100032

データ提供:米国国立医学図書館(NLM)

Evaluating the Effectiveness of Generic Antiretroviral Therapy for HIV

The fight against HIV/AIDS is a relentless journey across a vast and challenging desert. This research delves into the realm of generic antiretroviral therapy, a crucial tool for expanding access to treatment and improving the lives of people living with HIV. The study aims to evaluate the effectiveness and safety of a specific generic combination antiretroviral therapy regimen in HIV-infected patients who have never received treatment before.

The Promise of Generic Antiretroviral Therapy

This study demonstrates the effectiveness and safety of a specific generic antiretroviral regimen (lamivudine/tenofovir/efavirenz) in a group of HIV-infected patients who had never received treatment before. The study found that the generic regimen achieved significant reductions in viral load and increases in CD4 T-cell count, comparable to the effectiveness of the innovator drug regimen. This finding holds significant implications for expanding access to affordable and effective HIV treatment.

Expanding Access to HIV Treatment

This study highlights the potential of generic antiretroviral therapy to bridge the gap in access to HIV treatment. The findings provide compelling evidence for the efficacy and safety of generic regimens, supporting the use of generic drugs as a cost-effective and accessible option for HIV-infected individuals. This research offers hope for expanding access to life-saving treatments, improving outcomes for people living with HIV.

Dr. Camel's Conclusion

This research offers a compelling argument for the use of generic antiretroviral therapy in HIV treatment. The study's findings demonstrate the effectiveness and safety of a specific generic regimen, supporting the use of generics as a valuable tool for expanding access to affordable and effective treatment options. This research underscores the importance of ongoing efforts to combat HIV/AIDS, paving the way for a future where everyone has access to the care they need.

Date :
  1. Date Completed 2019-11-20
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

31095202

DOI: Digital Object Identifier

10.4067/S0716-10182019000100032

SNS
PICO Info
in preparation
Languages

Spanish

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.